الفهرس Only 14 pages are availabe for public view
 |  | from | 231 |  |  |
| | | from | 231 | | |
Abstract
In the current study 63 newly diagnosed HCC patients were recruited, between June 2012 and June 2013. 35 of them underwent TACE as a primary treatment modality (group A), while 28 of them (group B) were not candidates for immediate TACE. VEGF serum levels were measured using ELISA on days 0, 4, and 30 of TACE in group A, and days 0, 4, and 30 of recruitment in group which was considered a control group to assess potential variation of VEGF over time in the non-intervention group. VEGF serum level was found to correlate with advanced HCC tumor stage, with the higher levels observed in patients with more advanced disease. VEGF serum levels (baseline, day 4,and day 30) were also found to be predictive for PFS, OS, and response in HCC patients treated by TACE. Higher levels were associated with worse outcome